展品10.2

执行版本

股东压力位协议

本《股东服务协议》（本协议 “协议”），日期为2024年9月24日，由Breeze Holdings Acquisition Corp.，一个特拉华州 公司（“母公司。 ”），YD生物制药有限公司，一个开曼群岛特许公司（“公司”）， 以及公司的签署股东（每个人，“股东出售的普通股全部协议称为“”。股东”). 股东，公司和每位股东有时在本协议中分别称为“方一方当事人”。 未在本文件中另有定义但大写的术语应具有《合并协议》（如下定义）中赋予该等术语的含义。

前言

A. 2024年9月24日，母公司及全资子公司我公司，一个开曼群岛豁免有限公司，预计将更名为“YD Bio Holdings Limited”，该公司目前正处于母公司组建过程中，一旦组建完成，母公司将导致其加入本协议的加入条款（Pubco），股权兼并子公司Breeze Merger Sub, Inc.（下称Breeze），将成为Pubco的直接全资子公司，为特拉华州公司（“Parent Merger Sub指的是Elk Topco, LLC, a Bermuda limited liability company的一个直接全资子公司，是本协议的甲方。”），及Pubco的全资子公司，一个开曼群岛豁免公司将被更名为“BH Biopharma Merger Sub Limited”，目前正处于母公司组建过程中，一旦组建完成，母公司将导致其加入本协议的加入条款（Company Merger Sub），签署了某项关于合并协议和重组计划的协议（并购协议根据协议的规定，其中包括（a）母公司合并子公司将与母公司合并，母公司将继续作为存续公司（“Parent Merger”），并且母公司股东将获得Pubco的基本等价证券，以及（b）公司合并子公司将与公司合并，并且公司将继续作为存续公司（“公司合并”；公司合并和母公司合并在本文中统称为“Mergers）， 公司股东将收到Pubco普通股，并且作为并购的结果，上级公司和公司将成为Pubco的全资子公司，Pubco将根据并购协议中规定的条款和符合适用法律的规定，在Nasdaq上市，从而成为一家上市公司

b. 每位股东均为公司已发行且流通的普通股的记录和实际所有人，数量和类型如公司所示附表A以下称为“买方”。股份”).

C. 为了促使母公司和公司签订并购协议，促使初步股东签订赞助压力位协议，各方希望根据本协议的条款和条件签订本协议。

协议

因此，鉴于本文所述的前提和相互包含的承诺，以及其他良好和有价值的考虑，特此确认收悉并充分认可，各方各自意图受法律约束，特此达成如下协议：

1. 公司 股东同意及相关事项尽快合理时间内（但最迟在五（5）个工作日内）自注册声明根据证券法生效之时起，每位股东应（a）如实履行并向公司、上市公司和母公司交付书面同意书，该书面同意书构成必要批准，根据书面同意书，他们应无条件且不可撤销地（i）通过并批准并购协议，批准公司合并及公司作为一方参与的其他交易，（ii）根据公司组织文件的条款和条件，批准公司优先转换在结束前立即生效，且（iii）放弃他们根据开曼法可能拥有的关于公司合并及其他交易的任何鉴定或类似权利，以及（b）投票（或引发投票）其所有股东的股份（与此处日期后收购持有或享有投票权的公司股份一起，合称“受让公司股票”），反对，并就可能导致（i）违反公司在并购协议项下的任何陈述、保证、契约、协议或义务，或（ii）未满足并购协议第8.01或8.02节规定的任何结束条件而保留同意意见； 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；在个案中，根据条款（a）和（b），未经该股东同意不得修改并购协议（A）以减少根据并购协议应支付的总公司合并对价或（B）来改变总公司合并对价的形式，每位股东均确认收到并审核了并购协议副本。

2. 股票的转让每位股东均同意，不得直接或间接（a）卖出、转让（包括法律操作）、设定留置权、出质、抵押、授予购买选择权、分配、处置或以其他方式担保其任何主体公司股票，或以其他方式订立任何合同、选择权或其他安排或承诺执行上述任何行动（每一个，““转让”还将被视为发生在任何操作持有人(或该操作持有人的允许受让人)有B类普通股股份的非盈利机构(或该股份的任何受益人)持有该B类普通股股份的顶层支配权或独家投票权控制时，就该B类普通股股份而言，操作持有人(或其允许受让方)不再保留独立支配权(在操作持有人和其允许受让方之间)和其对该安全的投票或投票的独占支配权(包括通过委托、投票协议或其他方式)，情况下(在这种情况下)。即使是这种情况，以下任何情况也不被视为“转让”:”），（b）将其任何主体公司股票存入投票信托或订立与本协议中任何约定或协议相抵触的投票协议或安排，或授予任何有关其主体公司股票的代理人或授权委托书，导致其取得权利或势力与本协议中的任何约定或协议相冲突，或（c）采取任何可能导致阻碍或明显延误其在此项下的义务履行的行动； 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；, 公司对于以下情况，不应承担责任：根据第10（b）部分书面信息可靠地提供。，但前述规定不适用于任何转让（i）给该股东的关联公司，（ii）给是方当事人并受本协议条款和义务约束的另一股东，或（iii）在公司合并或其他交易中进行。 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；在此提请注意，对任何按照第(i)款所规定类型的转让受让方，必须签订加入协议，同意成为交易方。

3. 其他 契约和协议.

(a) [保留.]

(b) 每个 的股东特此同意受 (i) 第 7.04 (b) 节（保密）和第 7.11 节（公开公告）的约束并受其约束 合并协议的适用范围与此类条款适用于合并协议各方的程度相同，以及 (ii) 第 6.03 节（索赔） 针对信托账户）、合并协议第 7.03 节（必要批准）和第 7.05 节（非招标） 在每种情况下，此类规定适用于公司的程度， 作必要修改后 就好像该股东是其中的一方一样。 尽管本协议中有任何相反的规定，(x) 任何股东均不对公司的行为负责 或公司董事会（或其任何委员会）或任何高级职员、董事（以其身份）、员工或专业顾问 上述任何一项（”公司关联方”），包括与任何考虑的事项有关的问题 靠这个 第 3 (b) 节，(y) 没有股东对任何股东的行为作出任何陈述或保证 公司关联方以及 (z) 公司违反合并协议义务的任何行为均不予考虑 违反了这个规定 第 3 (b) 节 （为避免疑问，不言而喻，每位股东仍应为此负责 它对此的任何违规行为 第 3 (b) 节).

(c) 每一位股东均确认并同意，Pubco、母公司、母公司并购子公司和公司并购子公司正基于股东进入本协议并同意遵守、履行或以其他方式遵守本协议中包含的协议、契约和责任才进行并购协议，母公司初始股东基于股东进入本协议并同意遵守、履行或以其他方式遵守本协议中包含的协议、契约和责任，才会进入签署并购协议或同意完成交易，母公司和母公司并购子公司也不会进入签署并购协议或同意执行交易，母公司初始股东也不会进入开曼法国民商法的赞助支持协议或同意执行其中涉及的交易。

4. 股东 陈述与担保每位股东独立而非共同地向母公司和公司作出以下陈述与担保：

(a) 如果该股东是自然人，他或她具有法律能力来执行和遵守本协议。如果该股东不是自然人，则其依其注册或组织管辖法律合法组织，合法存在并且在良好状态下。

(b) 本协议之执行、签署和履行，以及本协议构思之交易的完成，均属该股东的权限范围内，并已经该股东采取所有必要行动来正式授权。

(c) 股东签署及交付本协议，不会造成冲突或违反适用于该股东的任何法律，且该股东履行本协议下的义务也不会：(i) 构成对其Subject Company Stock的任何留置权（除本协议、合并协议或附属协议之外）；(iii) 如果适用，与或违反其组织文件，或构成违约；(iv) 需要未在此日期前给予或完成的，任何人的同意、授权或批准，声明、提交或登记，或通知。

(d) There are no Actions pending against such Shareholder or, to the knowledge of such Shareholder, threatened against such Shareholder, before (or, in the case of threatened Actions, that would be before) any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such Shareholder of its obligations under this Agreement.

(e) This Agreement has been duly executed and delivered by such Shareholder and, assuming due authorization, execution and delivery by the other Parties, this Agreement constitutes a legally valid and binding obligation of such Shareholder, enforceable against him, her or it in accordance with the terms hereof (except as enforceability may be limited by applicable bankruptcy Laws, other applicable, similar Laws affecting creditors’ rights and general principles of equity affecting the availability of specific performance and other equitable remedies).

(f) Such Shareholder has not entered into, and shall not enter into, any agreement that would restrict, limit or interfere with the performance of his, her or its obligations hereunder.

(g) Such Shareholder is the exclusive record and beneficial owner of, and has good and valid title to, all of the Shares set forth opposite such Shareholder’s name on Schedule A hereto, and there exist no Liens, pledge, proxy, security interest, option, right of first refusal, adverse claim of ownership or any other limitations or restrictions (including, without limitation, any restriction on the right to vote, sell or otherwise dispose of such Shares), other than pursuant to (i) this Agreement, (ii) the Company Organizational Documents, (iii) the Merger Agreement or the Ancillary Agreements and (iv) any applicable securities Laws, and as of the date of this Agreement, such Shareholder has the sole power (as currently in effect) to vote, and the right, power and authority to sell, transfer and deliver, such Shares, and such Shareholder does not own, directly or indirectly, any other Shares.

5. Termination. This Agreement shall automatically terminate, without any notice or other action by any Party, upon the earliest of (a) the Company Merger Effective Time, (b) the termination of the Merger Agreement in accordance with its terms and (c) the mutual written agreement of all of the Parties. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i) the termination of this Agreement pursuant to Section 5(b) shall not affect any liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination or Fraud, (ii) Sections 5 and 10 shall each survive any termination of this Agreement pursuant to Section 5(a), and (iii) Sections 5 through 14 shall survive any termination of this Agreement. For purposes of this Section 5, “Fraud” means an act or omission by a Party, and requires: (A) a false or incorrect representation or warranty expressly set forth in this Agreement, (B) with actual knowledge (as opposed to constructive, imputed or implied knowledge) by the Party making such representation or warranty that such representation or warranty expressly set forth in this Agreement is false or incorrect, (C) an intention to deceive another Party to induce him, her or it to enter into this Agreement, (D) another Party, in justifiable or reasonable reliance upon such false or incorrect representation or warranty expressly set forth in this Agreement, causing such Party to enter into this Agreement, and (E) causing such Party to suffer damage by reason of such reliance.

6. No Recourse. Except for claims pursuant to the Merger Agreement or any other Ancillary Agreement by any party thereto against any other party thereto, each Party agrees that (a) this Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and no claims of any nature whatsoever (whether in tort, contract or otherwise) arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any Affiliate of the Company (other than the Shareholders, on the terms and subject to the conditions set forth herein) or any Affiliate of Parent, and (b) none of the Affiliates of the Company (other than the Shareholders, on the terms and subject to the conditions set forth herein) or the Affiliates of Parent shall have any liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions with respect to any information or materials of any kind furnished in connection with this Agreement, the negotiation hereof or the transactions contemplated hereby.

7. Notices. All notices and other communications among the Parties shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid, (c) when delivered by FedEx or other nationally recognized overnight delivery service or (d) when e-mailed during normal business hours (and otherwise as of the immediately following Business Day), addressed as follows:

Breeze Holdings Acquisition Corp.
955 W. John Carpenter Fwy., Suite 100-929
Irving, TX 75039
Attention: J. Douglas Ramsey, Ph.D.
Email: doug@breezeacquisition.com

with a copy to:

Woolery & Co.
1 Pier 76
408 12th Ave
New York, NY 10018
Attention: Jim Woolery; Mathew J. Saur
Email: james@wooleryco.com; matt@ekpyrosis.co

YD Biopharma Limited
12th Floor, No. 101, Section 2
Nanjing East Road, Zhongshan District
Taipei City, Taiwan 54186159
Attn: Dr. Ethan Shen
E-mail: ethanshen@eg-bio.com

with a copy to: 

ArentFox Schiff LLP
1717 K Street NW
Suite 700
Washington, DC 20006
Attention: Ralph V. De Martino
Email: ralph.demartino@afslaw.com

(c) If to a Shareholder, to the address or email address set forth for such Shareholder on his, her or its signature page hereof, or to such other address or addresses as the Parties may from time to time designate in writing.

8. Entire Agreement. This Agreement and the Merger Agreement constitute the entire agreement of the Parties with respect to the subject matter of this Agreement and supersede all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this Agreement.

9. Amendments and Waivers; Assignment. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Parties and the Parties to be bound thereby, respectively. Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable by any Party without the prior written consent of the other Parties.

10. Fees and Expenses. Except as otherwise expressly set forth in the Merger Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses.

11. Fiduciary Duties. Notwithstanding anything in this Agreement to the contrary, (a) none of the Shareholders makes any agreement or understanding herein in any capacity other than in its capacity as a record holder and beneficial owner of the Subject Company Stock and (b) nothing herein will be construed to limit or affect any action or inaction by any representative of such Shareholder in its capacity as a member of the Company Board or other similar governing body of any of its Affiliates or as an officer, employee or fiduciary of the Company or any of its Affiliates, in each case, acting in such person’s capacity as a director, officer, employee or fiduciary of the Company or such Affiliate.

12. Remedies. Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that a Party does not perform its respective obligations under the provisions of this Agreement in accordance with their specific terms or otherwise breaches such provisions. It is accordingly agreed that each Party shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each Party agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other Parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity.

13. No Third Party Beneficiaries. This Agreement shall be for the sole benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and permitted assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties acting as partners or participants in a joint venture.

14. Incorporation by Reference. Sections 1.03 (Construction), 10.03 (Severability), 10.06 (Governing Law), 10.07 (Waiver of Jury Trial), 10.08 (Headings) and 10.09 (Counterparts; Electronic Delivery) of the Merger Agreement are incorporated herein by reference and shall apply to this Agreement mutatis mutandis.

[Signature page follows]

IN WITNESS WHEREOF, each of the Parties has executed and delivered this Shareholder Support Agreement as of the date first above written.

[Signature Page to Shareholder Support Agreement]

IN WITNESS WHEREOF, each of the Parties has executed and delivered this Shareholder Support Agreement as of the date first above written.

[Signature Page to Shareholder Support Agreement]

IN WITNESS WHEREOF, each of the Parties has executed and delivered this Shareholder Support Agreement as of the date first above written.

[Signature Page to Shareholder Support Agreement]

SCHEDULE A

COMPANY SHARES